Hirullin P18
Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.
Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.
- Evidence level
- In vitro
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
Hirullin P18 is a preclinical synthetic peptide; its in vitro thrombin inhibition does NOT establish clinical efficacy. No FDA-approved derivative exists. Distinct from FDA-approved synthetic hirudin analog bivalirudin.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 2,300 Da
- Source species
- Hirudo medicinalis (synthetic derivative)
Biological Targets
- → thrombin
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.